Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within five days of administering the antiviral drug. There were no fatalities reported during the study
Tepmetko is the first and only oral MET inhibitor to be approved in the European Economic Area for treating adult patients with advanced NSCLC harboring alterations leading to METex14 skipping, who require systemic therapy following prior treatment
AROC3-1001 is a phase 1/2, placebo controlled, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-C3
Recall does not include any metabolic deficiency nutrition formulas
The partnership will help digitize and automate existing tasks traditionally managed on paper, significantly reducing costs and lead times while increasing compliance
Virginia will be responsible for meeting client needs for both media and commercial analytics.
Agilent will integrate the technology into its lab informatics platforms, enabling customers to automate GC/MS data analysis
Phase 2 clinical trial to begin in 2022 with participation by Cedars Sinai Medical Center, University of Utah, and City of Hope
Equity investment follows recent EUR 520 m licensing agreement providing Grand Pharma (GP) access to three of ITM’s targeted radionuclide therapeutic and diagnostic candidates for Greater China
The insights collected by the app will support the pharmaceutical industry’s efforts to further improve patients’ lives by providing actionable data on patients’ individual experiences
Subscribe To Our Newsletter & Stay Updated
